Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Lysiane Marthey; Christine Mateus; Charlotte Mussini; Maria Nachury; Stéphane Nancey; Florent Grange; Camille Zallot; Laurent Peyrin‐Biroulet; Jean‐François Rahier; Mario Beauregard; Laurent Mortier; Clélia Coutzac; Émilie Soularue; Émilie Lanoy; Nathalie Kapel; David Planchard; Nathalie Chaput; Caroline Robert; Franck Carbonnel

doi:10.1093/ecco-jcc/jjv227

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease. Rapid escalation to infliximab should be advocated in patients who do not respond to steroids. Patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marthey et al. (2016) studied this question.

synapsesocial.com/papers/69d94a919a6164e50fa3c792 https://doi.org/10.1093/ecco-jcc/jjv227

View Full Paper

Ask AI

Bookmark

Share

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading